Abstract
H-rev107-1 is a growth inhibitory RAS target gene capable of suppressing anchorage independent growth in vitro and in vivo. Using a tumour tissue array with 241 matched tumour and normal tissue cDNA pools, we found down-regulation of H-REV107-1 in 7 out of 14 ovary-derived cDNAs. RT–PCR analysis and immunohistochemical investigation confirmed expression of H-REV107-1 in normal ovarian epithelial cells but down-regulation in high grade ovarian carcinomas. H-REV107-1 is also strongly expressed in immortalized rat and human ovarian epithelial cells in vitro, but suppressed in transformed cells by two different mechanisms. KRAS-transformed rat ovarian cells and PA1 teratocarcinoma cells, reversibly repress H-REV107-1 via MAP/ERK signaling. In contrast, treatment of A27/80 and OVCAR-3 epithelial ovarian cancer cells with IFNγ stimulated H-REV107-1 expression. In NIH3T3 cells harbouring an estrogen-inducible IRF-1, H-rev107-1 is directly induced after activation of IRF-1, indicating that H-rev107-1 is a target of IRF-1. Stimulation of H-REV107-1 expression was also observed in ovarian epithelial cells suggesting that IRF-1 is involved in H-REV107-1 regulation in human ovarian epithelium. In the IFNγ-sensitive cell line A27/80, H-REV107-1 suppresses colony formation. A27/80 and OVCAR-3 cells overexpressing H-REV107-1 protein underwent apoptosis. These results demonstrate down-regulation of the class II tumour suppressor H-REV107-1 in human ovarian carcinomas and suggest an involvement of H-REV107-1 in interferon-dependent cell death.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Adams AT, Auersperg N . 1985 Exp. Cell Biol. 53: 181–188
Baldwin RL, Nemeth E, Tran H, Shvartsman H, Cass I, Narod S, Karlan BY . 2000 Cancer Res. 60: 5329–5333
Bist A, Fielding CJ, Fielding PE . 2000 Biochemistry 39: 1966–1972
Burke F, Smith PD, Crompton MR, Upton C, Balkwill FR . 1999 Br. J. Cancer 80: 1236–1244
Catteau A, Harris WH, Xu CF, Solomon E . 1999 Oncogene 18: 1957–1965
Chelbi-Alix MK, Pelicano L . 1999 Leukemia 13: 1167–1174
Contente S, Kenyon K, Rimoldi D, Friedman RM . 1990 Science 249: 796–798
Dameron KM, Volpert OV, Tainsky MA, Bouck N . 1994 Science 265: 1582–1584
De Maeyer E, De Maeyer-Guignard J . 1988 Interferons and other regulatory cytokines New York: John Wiley and Sons
DiSepio D, Ghosn C, Eckert RL, Deucher A, Robinson N, Duvic M, Chandraratna RA, Nagpal S . 1998 Proc. Natl. Acad. Sci. USA 95: 14811–14815
Evans TR, Kaye SB . 1999 Br. J. Cancer 80: 1–8
Green WB, Slovak ML, Chen IM, Pallavicini M, Hecht JL, Willman CL . 1999 Leukemia 12: 1960–1971
Hajnal A, Klemenz R, Schäfer R . 1993 Cancer Res. 53: 4670–4675
Hajnal A, Klemenz R, Schäfer R . 1994 Oncogene 9: 479–490
Hanahan D, Weinberg RA . 2000 Cell 100: 57–70
Harada H, Kondo T, Ogawa S, Tamura T, Kitagawa M, Tanaka N, Lamphier MS, Hirai H, Taniguchi T . 1994 Oncogene 9: 3313–3320
Husmann K, Sers C, Fietze E, Mincheva A, Lichter P, Schäfer R . 1998 Oncogene 17: 1305–1312
Jiang MC, Lin TL, Lee TL, Huang HT, Lin CL, Liao CF . 2001 Mol. Cell Biol. Res. Commun. 4: 353–358
Jones PA, Laird PW . 1999 Nat. Genet. 21: 163–167
Kirchhoff S, Hauser H . 1999 Oncogene 18: 3725–3736
Kirchhoff S, Koromilas AE, Schaper F, Grashoff M, Sonenberg N, Hauser H . 1995 Oncogene 11: 439–445
Kondo T, Minamino N, Nagamura-Inoue T, Matsumoto M, Taniguchi T, Tanaka N . 1997 Oncogene 15: 1275–1281
Kuchinke W, Hart RP, Jonakait GM . 1995 Neuroimmunomodulation 2: 347–355
Momparler RL, Bovenzi V . 2000 J. Cell Physiol. 183: 145–154
Nozawa H, Oda E, Ueda S, Tamura G, Maesawa C, Muto T, Taniguchi T, Tanaka N . 1998 Int. J. Cancer 77: 522–527
Oberhuber H, Seliger B, Schäfer R . 1995 Molec. Carc. 12: 198–204
Ouchi T, Lee SW, Ouchi M, Aaronson SA, Horvath CM . 2000 Proc. Natl. Acad. Sci. USA 97: 5208–5213
Palombella VJ, Maniatis T . 1992 Mol. Cell Biol. 12: 3325–3336
Patton SE, Martin ML, Nelsen LL, Fang X, Mills GB, Bast Jr RC, Ostrowski MC . 1998 Cancer Res. 58: 2253–2259
Rohwedel J, Guan K, Wobus AM . 1999 Cells Tissues Organs 165: 190–202
Ronglin X, van Wijnen AJ, van der Meijden C, Luong MX, Stein JL, Stein GS . 2001 J. Biol. Chem. 276: 18624–18632
Russell PA, Pharoah PD, De Foy K, Ramus SJ, Symmonds I, Wilson A, Scott I, Ponder BA, Gayther SA . 2000 Int. J. Cancer 87: 317–321
Sager R . 1997 Proc. Natl. Acad. Sci. USA 94: 952–955
Schäfer R . 1994 Reviews of Physiology, Biochemistry and Pharmacology 124: 29–92
Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW . 1997 Cell 88: 593–602
Sers C, Emenegger U, Husmann K, Bucher K, Andres A-C, Schäfer R . 1997 J. Cell. Biol. 136: 935–944
Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW . 1999 Nat. Genet. 21: 99–102
Tainsky MA, Cooper CS, Giovanella BC, Vande Woude GF . 1984 Science 225: 643–645
Tamura G, Ogasawara S, Nishizuka S, Sakata K, Maesawa C, Suzuki Y, Terashima M, Saito K, Satodate R . 1996 Cancer Res. 56: 612–615
Tamura T, Ishihara M, Lamphier MS, Tanaka N, Oishi I, Aizawa S, Matsuyama T, Mak TW, Taki S, Taniguchi T . 1995 Nature 376: 596–599
Tan RS, Taniguchi T, Harada H . 1996 Cancer Res. 56: 2417–2421
Tanaka N, Ishihara M, Kitagawa M, Harada H, Kimura T, Matsuyama T, Lamphier MS, Aizawa S, Mak TW, Taniguchi T . 1994a Cell 77: 829–839
Tanaka N, Ishihara M, Taniguchi T . 1994b Cancer Lett. 83: 191–196
Tanaka N, Taniguchi T . 2000 Semin. Cancer Biol. 10: 73–81
Tchernitsa OI, Zuber J, Sers C, Brinckman R, Britsch SK, Adams V, Schafer R . 1999 Oncogene 18: 5448–5454
Tnani M, Bayard BA . 1999 Biochim. Biophys. Acta 1451: r59–r72
Tsao S-W, Mok SC, Fey EG, Fletcher JA, Wan TSK, Chew E-C, Muto MG, Knapp RC, Berkowitz RS . 1995 Exp. Cell Res. 218: 499–507
Von Lintig FC, Dreilinger AD, Varki NM, Wallace AM, Casteel DE, Boss GR . 2000 Breast Cancer Res. Treat. 62: 51–62
Willman CL, Sever CE, Pallavicini MG, Harada H, Tanaka N, Slovak ML, Yamamoto H, Harada K, Meeker TC, List AF, Taniguchi T . 1993 Science 259: 968–970
Windbichler GH, Hausmaninger H, Stummvoll W, Graf AH, Kainz C, Lahodny J, Denison U, Muller-Holzner E, Marth C . 2000 Br. J. Cancer 82: 1138–1144
Yasukawa H, Sasaki A, Yoshimura A . 2000 Ann. Rev. Immunol. 18: 143–164
Yip-Schneider MT, Lin A, Barnard D, Sweeney CJ, Marshall MS . 1999 Int. J. Oncol. 15: 271–279
Zhang M, Maass N, Magit D, Sager R . 1997 Cell Growth Differ. 8: 179–186
Zhumabayeva B, Adhikari P . 2001 Clontechniques 16: 27–28
Zhumabayeva B, Diatchenko L, Chenchik A, Siebert PD . 2001 BioTechniques 30: 158–163
Zou Z, Gao C, Nagaich AK, Connell T, Saito S, Moul JW, Seth P, Appella E, Srivastava S . 2000 J. Biol. Chem. 275: 6051–6054
Zuber J, Tchernitsa OI, Hinzmann B, Schmitz A-C, Grips M, Hellriegel M, Sers C, Rosenthal A, Schäfer R . 2000 Nat. Genet. 24: 144–152
Acknowledgements
We are grateful for the technical assistance of Conny Gieseler and Jana Keil. We also thank Hans-Jörg Hauser for providing us the KA1-10/96-1A cells, T Maniatis for the IRF-1 expression plasmid and Sai-Wah Tsao for the HOSE cells. Our work was supported by the Deutsche Krebshilfe (grant 10-1273-SeI to C Sers).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sers, C., Husmann, K., Nazarenko, I. et al. The class II tumour suppressor gene H-REV107-1 is a target of interferon-regulatory factor-1 and is involved in IFNγ-induced cell death in human ovarian carcinoma cells. Oncogene 21, 2829–2839 (2002). https://doi.org/10.1038/sj.onc.1205377
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205377
Keywords
This article is cited by
-
Defunctionalizing intracellular organelles such as mitochondria and peroxisomes with engineered phospholipase A/acyltransferases
Nature Communications (2022)
-
Interferon regulatory factor-1 regulates cisplatin-induced apoptosis and autophagy in A549 lung cancer cells
Medical Oncology (2022)
-
A novel lncRNA ROPM-mediated lipid metabolism governs breast cancer stem cell properties
Journal of Hematology & Oncology (2021)
-
Relationship between polymorphisms of the lipid metabolism-related gene PLA2G16 and risk of colorectal cancer in the Chinese population
Functional & Integrative Genomics (2019)
-
Phospholipase A/Acyltransferase enzyme activity of H-rev107 inhibits the H-RAS signaling pathway
Journal of Biomedical Science (2014)